ADHD Remote Technology Study of Cardiometabolic Risk Factors and Medication Adherence

Summary

Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder, with a prevalence among adults of 2.5%. The disorder is diagnosed based on impairing levels of inattentive, hyperactive and impulsive behaviours. Most adults with ADHD present with additional mental health problems. Adults with ADHD have an increased risk to develop so-called cardiometabolic illnesses, such as type-2 diabetes, obesity and cardiovascular disease (e.g., heart failure). However, detailed knowledge about the screening, diagnosis and management of adults with ADHD and co-occurring cardiometabolic illnesses is lacking. The purpose of ART-CARMA is to (1) obtain real-world data from adults with ADHD daily life on the extent to which ADHD medication treatment and physical activity, individually and jointly, may influence cardiometabolic risks in adults with ADHD, and (2) obtain real-world data of patterns of taking ADHD medication and reasons for not taking medication, over a remote monitoring period of 12 months.

ART-CARMA benefits from the ADHD Remote Technology ('ART') assessment and monitoring system for adults with ADHD (developed by Kuntsi, Dobson, et al.), and the RADAR-base mobile-health platform to which it is linked (developed by Dobson et al; http://www.radar-base.org). ART consists of both active (e.g., questionnaires) and passive (smartphone and a wearable device) monitoring. ART-CARMA will use remote measurement technology (RMT) in adults with ADHD to carry out unobtrusive, real-time data collection over a continuous period of 12 months. By recruiting 300 adults from adult ADHD clinic waiting lists (and a partner/family member/close friend for each of them) and monitoring them remotely, we will obtain objectively measured data relevant to cardiometabolic risk profiles from their daily lives. By targeting the period before starting any ADHD medication through to starting treatment and the subsequent period, up to 12 months in total, we obtain real-time data on multiple parameters, including side effects, that can inform the personalisation of treatment.

Conditions

• Attention Deficit Hyperactivity Disorder
• Cardiovascular Diseases
• Medication Adherence

Sponsors & Collaborators

• South London and Maudsley NHS Foundation Trust

  collaborator OTHER

• Barnet, Enfield and Haringey Mental Health NHS Trust

  collaborator OTHER_GOV

• Hospital Universitari Vall d'Hebron Research Institute

  collaborator OTHER

• Empatica, Inc.

  collaborator INDUSTRY

• Örebro University, Sweden

  collaborator OTHER

• Concentris research management gmbh

  collaborator UNKNOWN

• Attention Deficit Disorder Information and Support Service

  collaborator UNKNOWN

• The European Association for the Study of Obesity

  collaborator UNKNOWN

• Northumberland, Tyne and Wear NHS Foundation Trust

  collaborator OTHER

• Tees, Esk and Wear Valleys NHS Foundation Trust

  collaborator UNKNOWN

• South West London and St George's Mental Health NHS Trust

  collaborator OTHER

• East London NHS Foundation Trust

  collaborator OTHER_GOV

• Avon and Wiltshire Mental Health Partnership NHS Trust

  collaborator OTHER_GOV

• King's College London

  lead OTHER

Principal Investigators

• Jonna Kuntsi, BSc, MSc, PhD · Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-12

Primary Completion

2025-03-31

Completion

2025-03-31

Countries

• Spain
• United Kingdom

Study Locations